Intellia exits hemophilia pact with Regeneron; Sangamo targets $24M raise

Plus, news about OKYO Pharma:

Intellia departs Regeneron deal: The CRISPR biotech disclosed Friday that it had opted out of a partnership with Regeneron to develop a factor IX gene editing therapy. The program was in preclinical studies, according to Intellia’s website. The partners had penned…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Click here to view Pennsylvania NY/NJ Biotech Networks Trending News